Disorders of Phosphorus Homeostasis

Overview

Journal Curr Opin Endocrinol Diabetes Obes

Specialty Endocrinology

Date 2010 Oct 22

PMID 20962635

Citations 2

Authors

Richard Lee

Thomas J Weber

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The study of phosphorus physiology and investigations into clinical disorders of phosphorus metabolism has blossomed over the past decade. Recent work has confirmed and further extended our knowledge of basic mechanisms of phosphorus metabolism.

Recent Findings: This review will focus on FGF-23 and Klotho, and on the recent further dissection of their roles in phosphorus and skeletal metabolism. Additionally, this review will detail recent studies that implicate a role for these phosphaturic and vitamin D regulating factors in extraskeletal calcification, including that occurring in soft tissue and vascular beds.

Summary: These findings in total provide fertile ground for investigations into the cause and treatment of abnormal skeletal and extraskeletal calcification in patients with inherited hypophosphatemic disorders. More importantly, and certainly with wider potential clinical application, these studies likewise imply a role for these factors in the pathogenesis of accelerated cardiovascular disease that occurs in patients with the most common hyperphosphatemic disorder, chronic kidney disease. Future studies are needed to confirm a harmful or possibly even beneficial role for FGF-23 and other factors in these disease states, and to determine whether therapeutic manipulation of these factors does truly affect clinical outcomes in patients with hypophosphatemia and hyperphosphatemia.

Citing Articles

Modulating phosphate consumption, a novel therapeutic approach for the control of cancer cell proliferation and tumorigenesis.

Arnst J, Beck Jr G Biochem Pharmacol. 2020; 183:114305.

PMID: 33129806 PMC: 9667393. DOI: 10.1016/j.bcp.2020.114305.

Examining the association between serum phosphate levels and leukocyte telomere length.

Yang Z, Kao T, Peng T, Chen Y, Yang H, Wu C Sci Rep. 2020; 10(1):5438.

PMID: 32214202 PMC: 7096403. DOI: 10.1038/s41598-020-62359-3.

References

Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N . Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009; 45(4):814-6. DOI: 10.1016/j.bone.2009.06.017. View

Galitzer H, Ben-Dov I, Silver J, Naveh-Many T . Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2009; 77(3):211-8. DOI: 10.1038/ki.2009.464. View

Saleh H, Baker H . Aspiration biopsy cytology of tumoral calcinosis: a case report. Acta Cytol. 2009; 53(3):323-6. DOI: 10.1159/000325318. View

Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom T . Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet. 2010; 86(2):267-72. PMC: 2820166. DOI: 10.1016/j.ajhg.2010.01.006. View

Ohnishi M, Nakatani T, Lanske B, Razzaque M . Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int. 2009; 75(11):1166-1172. PMC: 3143194. DOI: 10.1038/ki.2009.24. View

Gutierrez O, Mannstadt M, Isakova T, Rauh-Hain J, Tamez H, Shah A . Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359(6):584-92. PMC: 2890264. DOI: 10.1056/NEJMoa0706130. View

Bergwitz C, Banerjee S, Abu-Zahra H, Kaji H, Miyauchi A, Sugimoto T . Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis. J Clin Endocrinol Metab. 2009; 94(11):4267-74. PMC: 2775647. DOI: 10.1210/jc.2009-0961. View

Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K . Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2009; 77(3):232-8. DOI: 10.1038/ki.2009.414. View

Friedman D, Afkarian M, Tamez H, Bhan I, Isakova T, Wolf M . Klotho variants and chronic hemodialysis mortality. J Bone Miner Res. 2009; 24(11):1847-55. PMC: 2765930. DOI: 10.1359/jbmr.090516. View

10.

Quarles L . Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008; 118(12):3820-8. PMC: 2586800. DOI: 10.1172/JCI36479. View

11.

Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T . Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390(6655):45-51. DOI: 10.1038/36285. View

12.

Hsu H, Wu M . Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009; 337(2):116-22. DOI: 10.1097/MAJ.0b013e3181815498. View

13.

Razzaque M . Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372. Expert Opin Ther Pat. 2010; 20(7):981-5. PMC: 2925134. DOI: 10.1517/13543771003774100. View

14.

Ohnishi M, Razzaque M . Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J. 2010; 24(9):3562-71. PMC: 2923352. DOI: 10.1096/fj.09-152488. View

15.

Jean G, Terrat J, Vanel T, Hurot J, Lorriaux C, Mayor B . High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009; 24(9):2792-6. DOI: 10.1093/ndt/gfp191. View

16.

Ichikawa S, Sorenson A, Austin A, Mackenzie D, Fritz T, Moh A . Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology. 2009; 150(6):2543-50. PMC: 2689800. DOI: 10.1210/en.2008-0877. View

17.

Liang G, Katz L, Insogna K, Carpenter T, Macica C . Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice. Calcif Tissue Int. 2009; 85(3):235-46. PMC: 2988401. DOI: 10.1007/s00223-009-9270-6. View

18.

Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I . Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009; 24(11):1879-88. DOI: 10.1359/jbmr.090509. View

19.

Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V . Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet. 2010; 86(2):273-8. PMC: 2820183. DOI: 10.1016/j.ajhg.2010.01.010. View

20.

Nakatani T, Ohnishi M, Razzaque M . Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J. 2009; 23(11):3702-11. PMC: 2775000. DOI: 10.1096/fj.08-123992. View